Clinical immunology (Orlando, Fla.) · 2024
Consensus gene modules strategy identifies candidate blood-based biomarkers for primary Sjögren's disease.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boudjeniba Cheïma, Soret Perrine, Trutschel Diana, Hamon Antoine, Baloche Valentin, Chassagnol Bastien, Desvaux Emiko, Bichat Antoine, Aussy Audrey, Moingeon Philippe, Lefebvre Céline, Hubert Sandra, Alarcon-Riquelmé Marta, Ng Wan-Fai, Gottenberg Jacques-Eric, Schwikowski Benno, Bombardieri Michele, van Roon Joel A G, Mariette Xavier, Guedj Mickaël, Birmele Etienne, Laigle Laurence, Becht Etienne
Аннотация
Primary Sjögren disease (pSD) is an autoimmune disease characterized by lymphoid infiltration of exocrine glands leading to dryness of the mucosal surfaces and by the production of autoantibodies. The pathophysiology of pSD remains elusive and no treatment with demonstrated efficacy is available yet. To better understand the biology underlying pSD heterogeneity, we aimed at identifying Consensus gene Modules (CMs) that summarize the high-dimensional transcriptomic data of whole blood samples in pSD patients. We performed unsupervised gene classification on four data sets and identified thirteen CMs. We annotated and interpreted each of these CMs as corresponding to cell type abundances or biological functions by using gene set enrichment analyses and transcriptomic profiles of sorted blood cell subsets. Correlation with independently measured cell type abundances by flow cytometry confirmed these annotations. We used these CMs to reconcile previously proposed patient stratifications of pSD. Importantly, we showed that the expression of modules representing lymphocytes and erythrocytes before treatment initiation is associated with response to hydroxychloroquine and leflunomide combination therapy in a clinical trial. These consensus modules will help the identification and translation of blood-based predictive biomarkers for the treatment of pSD.